Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Seena Magowitz Phase IB/II Trial of CMP-001 (a TLR9 Agonist) in Combination With INCAGN01949 (an Activating Anti-OX40 Antibody) for In Situ Intratumoral Injection for Patients With Stage IV Pancreatic and Other Cancers Except Melanoma

NCT04387071 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT04387071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04387071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Seena Magowitz Phase IB/II Trial of CMP-001 (a TLR9 Agonist) in Combination With INCAGN01949 (an Activating Anti-OX40 Antibody) for In Situ Intratumoral Injection for Patients With Stage IV Pancreatic and Other Cancers Except Melanoma
Lead sponsor
University of Southern California
Phase
Phase 1/2
Overall status
Terminated
Start date
April 29, 2021
Completion date
December 28, 2022
Enrollment
2 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced malignant solid neoplasm, metastatic pancreatic adenocarcinoma, stage iv pancreatic cancer ajcc v8, unresectable malignant solid neoplasm